Joe Levy

AHRQ-funded researchers calculated the US could save $150M every year by switching from low molecular weight heparin to aspirin for blood clot prevention in orthopedic trauma patients. (That grant cost <$100K.) pubmed.ncbi.nlm.nih.gov/40668732/

@joeymattingly @NEJM Ski bum picture!

Thanks to Stephen Morrissey @NEJM for having a conversation with me about our new article! Link below. Interview with Joey Mattingly on providing widespread access to HCV treatment at the lowest possible price. | New England Journal of Medicine nejm.org/do/10.1056/NEJ…

Very interesting to get a deeper look at what Medicare coverage of the weight loss drugs might cost, taking into account existing rebates & considering the counterfactual that many are likely to gain coverage through other indications over time regardless.

Tough day for a 🚨new paper🚨, but nevertheless! How much would it cost if Medicare was allowed to cover drugs approved for weight loss? We estimate $3.1-6.1 billion per year in the near term. Just out in @Health_Affairs (with @jlevy2) healthaffairs.org/doi/10.1377/hl…

And go.....

🚨 New publication alert 🚨 I am so excited to share that I published part of my dissertation work in JAMA HF. A huge thank you to these co-authors: @KellyAnders0n, @jlevy2, @healthecon_dan, and the twitterless Thomas V Johnson and Jerry Anderson jamanetwork.com/journals/jama-…

@Angela_HSR Congratulations Angela!!

Angela Liu, PhD I successfully defended my dissertation earlier this month. A perfect day surrounded by family and friends 🥳 Thrilled to share that I'll be joining Hopkins HPM faculty as an Assistant Scientist. Ready to get to work!

We've drafted a response to the recent CMS RFI on additional data collection to study the Medicare Advantage program. Want to sign on? Send me an email by Friday March 8th docs.google.com/document/d/1T1…

FDA approval of 2nd potent GLP-1 for treatment of obesity - Lilly’s drug Zepbound - will accelerate discounting as competition heats up, reducing costs and extending access to patients. A prior @AEIecon analysis captured magnitude of earlier discounts aei.org/wp-content/upl…

@a_kaltenboeck Sorry!I missed this reply! I was not talking about list price.I was saying a good model of how prices will now evolve(absent competition) bc of IRA is net prices will increase by CPI from launch,until 9year=small molecule,13y=biologic, and then drop by min of 25% @dollendorf

@jlevy2 Your point on the launch price is fair. Can you point me to the literature on the list price increases and 25% price drop in year 8 without competition?

This argument is a real doozy: we should apparently account for lower drug prices over time in cost effectiveness analysis. But that’s not the American experience. Our drug prices go up! Ex: Pfizer just doubled the price of Paxlovid… 1/ @DavidP4AD @DrEricDing @VincentRK

Ozempic, Wegovy, and other GLP-1s perfectly illustrate the common (and large) gaps between list and net prices of many brand drugs. A summary of our work: "Ozempic and Wegovy Don’t Cost What You Think They Do" via @nytimes nytimes.com/2023/10/22/hea…

@a_kaltenboeck absent novel competition a now reasonable assumption is that drug prices will increase by inflation for ~7 years, then in year 8 should drop 25% (or more). If new competition enters, new CEAs that take this into account are required, and the old CEAs become irrelevant (2/2)

@a_kaltenboeck Any CEA conducted by CMS (or anyone) will know the launch price, so I don't think that is what they are arguing, of course CEA models should use the new (and I agree) likely higher launch prices. This is about how the price estimate built into the CEA should change over time(1/2)

Hmm: New @AEI study estimates huge #GrossToNetBubble for GLP-1 #drugs. Net prices far below list prices due to #PBM #rebates & manuf copay support 👇 Perhaps economic impact has been overestimated? Full report: drugch.nl/3tiWRCB

Now in print, @jlevy2 and I test whether coverage of brand drugs in Part D differs based on whether the drug is a "good" or "bad" value relative to cost-effectiveness estimates. In short, it does not. aei.org/research-produ…

@dollendorf @icer_review @TuftsCEVR Congratulations Dan, wonderful news!

Defining “the price” of brand drugs like Ozempic can be complex. Our white paper summarizes what we know about the prices of new treatments for diabetes and obesity Short story: Very big differences between list and net prices, even adjusting for coupons aei.org/research-produ…

CMS will use comparative effectiveness to adjust the starting point in price negotiations, but how exactly? We adapted the French system (added benefit ratings linked to domestic reference prices) to model one approach and estimate savings. @jlevy2 valueinhealthjournal.com/article/S1098-…

New paper out in @health_affairs In Medicare Advantage, less use of longitudinal home-based medical care but substantially greater use of one-time home-based medical visits (likely related to diagnosis coding) than in traditional Medicare healthaffairs.org/doi/full/10.13…